Sustained release of tumor cell lysate and CpG from an injectable, cytotoxic hydrogel for melanoma immunotherapy
Kui Yang, Yuhan Zhou, Biwang Huang, Guifang Zhao, Geng Yuan, Chao Wan, Fagang Jiang, Honglin Jin, Chengzhi Ye, Jing Chen
Abstract
, MCL not only exerted direct antitumor activity, but also had robust immune initiation effects including the activation of dendritic cells in draining lymph nodes and the infiltration of cytotoxic T lymphocytes (CTLs) in tumor microenvironment. In addition, MCL can efficiently inhibit melanoma growth in B16-F10 tumor bearing mice, which suggested that MCL is a potential cancer vaccine strategy for melanoma treatment.
Topics & Concepts
Cytotoxic T cellMelittinCancer researchMelanomaImmunotherapyCancer immunotherapyAdjuvantImmune systemImmunogenicityTumor microenvironmentCD8T cellCpG OligodeoxynucleotideImmunologyMedicineChemistryIn vitroPeptideBiochemistryGeneDNA methylationGene expressionImmunotherapy and Immune ResponsesAntimicrobial Peptides and Activitiesvaccines and immunoinformatics approaches